.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dr Joshua Benner Discusses the Importance of PQA's New Opioid Measures

Published on: May 19, 2015

The new opioid quality measures by the Pharmacy Quality Alliance are a first step forward for improving use of prescription opioids.

At its 10th Annual Meeting in Arlington, Virginia, the Pharmacy Quality Alliance announced its new opioid quality measures, and RxAnte helped in the development and testing of these measures, explained Joshua Benner, PharmD, ScD, executive vice president of strategy and corporate development at Millennium Health and former president and chief executive officer of RxAnte.

The measures are just a first step, but what is important is that they develop a common definition of what appropriate use of prescription opioids actually is, Dr Benner said.

"As we develop experience using those measures in practice, we'll learn more about how they should be refined over time," he said.